Fundraising FoxTaiho Ventures, LLC — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsLifelinkMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer Ventures+1 more
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesUTokyo Innovation Platform Co. Ltd.+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.